Although SGLT-2 inhibitors show great potential in treating non-diabetic CKD, their use requires careful management of potential side effects, such as urinary tract infections, hypotension, and diabetic ketoacidosis (11). The gene discussed is SLC5A2; the disease is urinary tract infection.